Document is current
Any future updates will be listed below
-
Authors
Wall, J. S.
Williams, A. D.
Balachandran, M.
Hancock, T. J.
Richey, T.
Stuckey, A. C.
Macy, S.
Wooliver, C.
Martin, E. B.
Jackson, J. W.
Heidel, R. E.
Guthrie, S.
Klein, M. L.
Angell, N.
Kennel, S. J.
Foster, J. S.
-
Funding
Funding for this research was provided by:
Attralus, Inc. (Collaborative Research Award)
- License Information
-
More Information
Article History
Received: 18 March 2025
Accepted: 27 May 2025
First Online: 4 August 2025
Competing interests
: TR, AS, EM, and SK are founding shareholders of Attralus, Inc. JW is a founding shareholder and interim CSO of Attralus, Inc. SG is a founding shareholder and COO of Attralus, Inc. JW, SK, AW, TH, S,G and JF have rights in intellectual property related to antibody-peptide fusion proteins. SG, MK, and NA are employees and shareholders of Attralus, Inc.
